3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
19
Neoplasm Metastasis
3
Neoplasms
2
Bulbo-Spinal Atrophy, X-Linked
2
Salivary Gland Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer Metastatic Disease
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Ovarian Neoplasms
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Colorectal Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Bites and Stings
1
Advanced Solid Tumor
1
Adenocarcinoma
1
Interventions
relugolix
2
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2
Specimen Handling
2
Radiotherapy
2
Radiation
2
Magnetic Resonance Spectroscopy
2
Leuprolide
2
Goserelin
2
Biopsy
2
radium Ra 223 dichloride
1
luprolide acetate gel depot
1
histrelin
1
gallium 68 PSMA-11
1
enzalutamide
1
darolutamide
1
bicalutamide
1
Triptorelin Pamoate
1
Surgical Procedures, Operative
1
Salicylic Acid
1
Radiotherapy, Image-Guided
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Flutamide
1
Buserelin
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Prostate Adenocarcinoma
×
abiraterone
×
90 days
×
Clear all
No trials found.